1. Home
  2. WHWK vs ABOS Comparison

WHWK vs ABOS Comparison

Compare WHWK & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Whitehawk Therapeutics Inc.

WHWK

Whitehawk Therapeutics Inc.

SELL

Current Price

$3.01

Market Cap

164.8M

Sector

Health Care

ML Signal

SELL

Logo Acumen Pharmaceuticals Inc.

ABOS

Acumen Pharmaceuticals Inc.

HOLD

Current Price

$0.20

Market Cap

165.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WHWK
ABOS
Founded
2007
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.8M
165.6M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
WHWK
ABOS
Price
$3.01
$0.20
Analyst Decision
Buy
Hold
Analyst Count
9
6
Target Price
★ $7.71
$1.00
AVG Volume (30 Days)
366.3K
★ 5.5M
Earning Date
11-09-2026
10-26-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 86.02
N/A
EPS
★ N/A
N/A
Revenue
★ $7,145,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.97
$0.19
52 Week High
$5.50
$3.60

Technical Indicators

Market Signals
Indicator
WHWK
ABOS
Relative Strength Index (RSI) 40.04 20.91
Support Level $2.88 $0.19
Resistance Level $3.88 $2.84
Average True Range (ATR) 0.21 0.06
MACD 0.01 -0.03
Stochastic Oscillator 12.50 0.39

Price Performance

Historical Comparison
WHWK
ABOS

About WHWK Whitehawk Therapeutics Inc.

Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Share on Social Networks: